{"filing":{"accession_number":"0001654954-26-006949","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"a1493o.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426006949/a1493o.htm"},"events":[{"id":20992,"run_id":18916,"accession_number":"0001654954-26-006949","anchor_item_number":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is GSK's Q2 2026 financial results announcement, disclosing quarterly turnover of £8.4 billion (+5% CER), core operating profit growth of +7%, and core EPS growth of +9%. The document presents comprehensive financial performance metrics, segment results, and forward guidance for full-year 2026, which are hallmarks of a quarterly earnings release. Material to investors assessing the registrant's operational and financial performance.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-28","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":20518,"accession_number":"0001654954-26-006949","item_number":null,"item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is GSK's Q2 2026 financial results announcement, disclosing quarterly turnover of £8.4 billion (+5% CER), core operating profit growth of +7%, and core EPS growth of +9%. The document presents comprehensive financial performance metrics, segment results, and forward guidance for full-year 2026, which are hallmarks of a quarterly earnings release. Material to investors assessing the registrant's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T16:51:39.755264+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-28"}]}